GKOS Glaukos Corporation

NYSE
$184.53

Glaukos Corporation (GKOS) is expected to report earnings on October 28, 2026, after the market close. The consensus earnings estimate is a loss of $0.13 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +2.4% since its last earnings release on July 29, 2026.

Glaukos Beat Consensus Estimates, Raises Guidance
Wednesday, July 29, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Oct 28
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.13)
Rev est $154.92M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $175.13

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Glaukos Corporation

Glaukos is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.

Sector

Healthcare

Industry

Medical Appliances/Equipment